{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T07:05:36Z","timestamp":1794639936737,"version":"4.9.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R37CA241486-01A1"],"award-info":[{"award-number":["R37CA241486-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH2210197"],"award-info":[{"award-number":["W81XWH2210197"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["23YOUNG15"],"award-info":[{"award-number":["23YOUNG15"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008746","name":"National Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008746","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-69308-0","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T01:33:05Z","timestamp":1771637585000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Crosstalk between EZH2 and DNA methylation mediates neuroendocrine prostate cancer lineage plasticity"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3730-496X","authenticated-orcid":false,"given":"Richa","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7071-4584","authenticated-orcid":false,"given":"Varadha Balaji","family":"Venkadakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eddie","family":"Imada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutaka","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2928-0232","authenticated-orcid":false,"given":"Nicholas J.","family":"Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9935-2830","authenticated-orcid":false,"given":"Kate E.","family":"Dunmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Garner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Booker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4580-649X","authenticated-orcid":false,"given":"Brian","family":"Hanratty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Haffner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9134-8808","authenticated-orcid":false,"given":"Michael Y.","family":"Tolstorukov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7336-8071","authenticated-orcid":false,"given":"Luigi","family":"Marchionni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5374-890X","authenticated-orcid":false,"given":"Brian D.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7420-5883","authenticated-orcid":false,"given":"David S.","family":"Rickman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3259-2226","authenticated-orcid":false,"given":"Himisha","family":"Beltran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,21]]},"reference":[{"key":"69308_CR1","doi-asserted-by":"publisher","unstructured":"Flavahan, W.A., Gaskell, E., and Bernstein, B,E. Epigenetic plasticity and the hallmarks of cancer. Science https:\/\/doi.org\/10.1126\/science.aal2380.ncbi.nlm.nih.gov\/pubmed\/28729483 (2017).","DOI":"10.1126\/science.aal2380.ncbi.nlm.nih.gov\/pubmed\/28729483"},{"key":"69308_CR2","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1593\/neo.122146","volume":"15","author":"PC Lin","year":"2013","unstructured":"Lin, P. C. et al. Epigenomic alterations in localized and advanced prostate cancer. Neoplasia 15, 373\u2013383 (2013).","journal-title":"Neoplasia"},{"key":"69308_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34012-2","volume":"13","author":"S Chen","year":"2022","unstructured":"Chen, S. et al. The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors. Nat. Commun. 13, 6467 (2022).","journal-title":"Nat. Commun."},{"key":"69308_CR4","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/s41588-020-0648-8","volume":"52","author":"SG Zhao","year":"2020","unstructured":"Zhao, S. G. et al. The DNA methylation landscape of advanced prostate cancer. Nat. Genet 52, 778\u2013789 (2020).","journal-title":"Nat. Genet"},{"key":"69308_CR5","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1158\/2159-8290.CD-23-0754","volume":"14","author":"GM Franceschini","year":"2024","unstructured":"Franceschini, G. M. et al. Noninvasive detection of neuroendocrine prostate cancer through targeted cell-free DNA methylation. Cancer Discov. 14, 424\u2013445 (2024).","journal-title":"Cancer Discov."},{"key":"69308_CR6","doi-asserted-by":"publisher","first-page":"4159","DOI":"10.1128\/MCB.00235-10","volume":"30","author":"SR Kinney","year":"2010","unstructured":"Kinney, S. R. et al. Opposing roles of Dnmt1 in early- and late-stage murine prostate cancer. Mol. Cell Biol. 30, 4159\u20134174 (2010).","journal-title":"Mol. Cell Biol."},{"key":"69308_CR7","doi-asserted-by":"crossref","unstructured":"Luo, C. et al. Global DNA methylation remodeling during direct reprogramming of fibroblasts to neurons. Elife. 8, e40197 (2019).","DOI":"10.7554\/eLife.40197"},{"key":"69308_CR8","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1523\/JNEUROSCI.4037-15.2016","volume":"36","author":"A Sharma","year":"2016","unstructured":"Sharma, A., Klein, S. S., Barboza, L., Lohdi, N. & Toth, M. Principles governing DNA methylation during neuronal lineage and subtype specification. J. Neurosci. 36, 1711\u20131722 (2016).","journal-title":"J. Neurosci."},{"key":"69308_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3389\/fnins.2018.00005","volume":"12","author":"SH Stricker","year":"2018","unstructured":"Stricker, S. H. & G\u00f6tz, M. DNA-methylation: master or slave of neural fate decisions? Front Neurosci. 12, 5 (2018).","journal-title":"Front Neurosci."},{"key":"69308_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2013-14-3-r25","volume":"14","author":"JP Reddington","year":"2013","unstructured":"Reddington, J. P. et al. Redistribution of H3K27me3 upon DNA hypomethylation results in de-repression of Polycomb target genes. Genome Biol. 14, R25 (2013).","journal-title":"Genome Biol."},{"key":"69308_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12915-020-0752-3","volume":"18","author":"DS Dunican","year":"2020","unstructured":"Dunican, D. S. et al. Bivalent promoter hypermethylation in cancer is linked to the H327me3\/H3K4me3 ratio in embryonic stem cells. BMC Biol. 18, 25 (2020).","journal-title":"BMC Biol."},{"key":"69308_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-018-1390-8","volume":"19","author":"Y Li","year":"2018","unstructured":"Li, Y. et al. Genome-wide analyses reveal a role of Polycomb in promoting hypomethylation of DNA methylation valleys. Genome Biol. 19, 18 (2018).","journal-title":"Genome Biol."},{"key":"69308_CR13","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.ccell.2016.09.005","volume":"30","author":"E Dardenne","year":"2016","unstructured":"Dardenne, E. et al. N-Myc induces an EZH2-mediated transcriptional program driving neuroendocrine prostate cancer. Cancer Cell 30, 563\u2013577 (2016).","journal-title":"Cancer Cell"},{"key":"69308_CR14","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/s41556-021-00743-5","volume":"23","author":"A Davies","year":"2021","unstructured":"Davies, A. et al. An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer. Nat. Cell Biol. 23, 1023\u20131034 (2021).","journal-title":"Nat. Cell Biol."},{"key":"69308_CR15","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1126\/science.aah4199","volume":"355","author":"SY Ku","year":"2017","unstructured":"Ku, S. Y. et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science 355, 78\u201383 (2017).","journal-title":"Science"},{"key":"69308_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51156-5","volume":"15","author":"VB Venkadakrishnan","year":"2024","unstructured":"Venkadakrishnan, V. B. et al. Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes. Nat. Commun. 15, 6779 (2024).","journal-title":"Nat. Commun."},{"key":"69308_CR17","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.4045","volume":"22","author":"H Beltran","year":"2016","unstructured":"Beltran, H. et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat. Med 22, 298\u2013305 (2016).","journal-title":"Nat. Med"},{"key":"69308_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04495-z","volume":"9","author":"L Puca","year":"2018","unstructured":"Puca, L. et al. Patient derived organoids to model rare prostate cancer phenotypes. Nat. Commun. 9, 2404 (2018).","journal-title":"Nat. Commun."},{"key":"69308_CR19","doi-asserted-by":"publisher","first-page":"e2100096","DOI":"10.1002\/adma.202100096","volume":"34","author":"MJ Mosquera","year":"2022","unstructured":"Mosquera, M. J. et al. Extracellular matrix in synthetic hydrogel-based prostate cancer organoids regulate therapeutic response to EZH2 and DRD2 inhibitors. Adv. Mater. 34, e2100096 (2022).","journal-title":"Adv. Mater."},{"key":"69308_CR20","doi-asserted-by":"publisher","first-page":"4611","DOI":"10.1016\/j.molcel.2022.11.010","volume":"82","author":"KW Fong","year":"2022","unstructured":"Fong, K. W. et al. PALI1 promotes tumor growth through competitive recruitment of PRC2 to G9A-target chromatin for dual epigenetic silencing. Mol. Cell 82, 4611\u20134626 (2022).","journal-title":"Mol. Cell"},{"key":"69308_CR21","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1016\/j.celrep.2019.10.031","volume":"29","author":"K McLaughlin","year":"2019","unstructured":"McLaughlin, K. et al. DNA methylation directs polycomb-dependent 3d genome re-organization in naive pluripotency. Cell Rep. 29, 1974\u20131985.e6 (2019).","journal-title":"Cell Rep."},{"key":"69308_CR22","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1101\/gr.133728.111","volume":"22","author":"AB Brinkman","year":"2012","unstructured":"Brinkman, A. B. et al. Sequential ChIP-bisulfite sequencing enables direct genome-scale investigation of chromatin and DNA methylation cross-talk. Genome Res 22, 1128\u20131138 (2012).","journal-title":"Genome Res"},{"key":"69308_CR23","doi-asserted-by":"publisher","first-page":"3274","DOI":"10.1016\/j.celrep.2019.08.046","volume":"28","author":"B Kumar","year":"2019","unstructured":"Kumar, B. & Els\u00e4sser, S. J. Quantitative multiplexed ChIP reveals global alterations that shape promoter bivalency in ground state embryonic stem cells. Cell Rep. 28, 3274\u20133284.e5 (2019).","journal-title":"Cell Rep."},{"key":"69308_CR24","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.stem.2018.10.017","volume":"24","author":"G van Mierlo","year":"2019","unstructured":"van Mierlo, G. et al. Integrative proteomic profiling reveals PRC2-dependent epigenetic crosstalk maintains ground-state pluripotency. Cell Stem Cell 24, 123\u2013137.e8 (2019).","journal-title":"Cell Stem Cell"},{"key":"69308_CR25","doi-asserted-by":"crossref","unstructured":"Lee, HM. et al. Epigenome reprogramming through H3K27 and H3K4 trimethylation as a resistance mechanism to DNA methylation inhibition in BRAFV600E-mutated colorectal cancer. Clin Cancer Res. 30, 5166\u20135179 (2024).","DOI":"10.1158\/1078-0432.CCR-24-1166"},{"key":"69308_CR26","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/1878-0261.12157","volume":"12","author":"K Dimopoulos","year":"2018","unstructured":"Dimopoulos, K. et al. Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner. Mol. Oncol. 12, 180\u2013195 (2018).","journal-title":"Mol. Oncol."},{"key":"69308_CR27","doi-asserted-by":"publisher","first-page":"eadk4423","DOI":"10.1126\/sciadv.adk4423","volume":"10","author":"AA Chomiak","year":"2024","unstructured":"Chomiak, A. A. et al. Select EZH2 inhibitors enhance viral mimicry effects of DNMT inhibition through a mechanism involving NFAT:AP-1 signaling. Sci. Adv. 10, eadk4423 (2024).","journal-title":"Sci. Adv."},{"key":"69308_CR28","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1158\/2159-8290.CD-19-1493","volume":"10","author":"G Deblois","year":"2020","unstructured":"Deblois, G. et al. Epigenetic switch-induced viral mimicry evasion in chemotherapy-resistant breast cancer. Cancer Discov. 10, 1312\u20131329 (2020).","journal-title":"Cancer Discov."},{"key":"69308_CR29","doi-asserted-by":"publisher","first-page":"3901","DOI":"10.1016\/j.molcel.2022.09.007","volume":"82","author":"Y Li","year":"2022","unstructured":"Li, Y. et al. Histone methylation antagonism drives tumor immune evasion in squamous cell carcinomas. Mol. Cell 82, 3901\u20133918.e7 (2022).","journal-title":"Mol. Cell"},{"key":"69308_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23780-y","volume":"12","author":"NJ Brady","year":"2021","unstructured":"Brady, N. J. et al. Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer. Nat. Commun. 12, 3372 (2021).","journal-title":"Nat. Commun."},{"key":"69308_CR31","doi-asserted-by":"crossref","unstructured":"Qiu, X. et al. Response to supraphysiological testosterone is predicted by a distinct androgen receptor cistrome. JCI Insight. 7, e157164 (2022).","DOI":"10.1172\/jci.insight.157164"},{"key":"69308_CR32","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1002\/pros.23313","volume":"77","author":"HM Nguyen","year":"2017","unstructured":"Nguyen, H. M. et al. LuCaP prostate cancer patient-derived xenografts reflect the molecular heterogeneity of advanced disease an\u2013d serve as models for evaluating cancer therapeutics. Prostate 77, 654\u2013671 (2017).","journal-title":"Prostate"},{"key":"69308_CR33","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.cell.2006.02.041","volume":"125","author":"BE Bernstein","year":"2006","unstructured":"Bernstein, B. E. et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125, 315\u2013326 (2006).","journal-title":"Cell"},{"key":"69308_CR34","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/path.6216","volume":"262","author":"RA Patel","year":"2024","unstructured":"Patel, R. A. et al. Characterization of HOXB13 expression patterns in localized and metastatic castration-resistant prostate cancer. J. Pathol. 262, 105\u2013120 (2024).","journal-title":"J. Pathol."},{"key":"69308_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3729-z","volume":"17","author":"HK Tsai","year":"2017","unstructured":"Tsai, H. K. et al. Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma. BMC Cancer 17, 759 (2017).","journal-title":"BMC Cancer"},{"key":"69308_CR36","doi-asserted-by":"publisher","first-page":"eadf6732","DOI":"10.1126\/scitranslmed.adf6732","volume":"15","author":"Y Yamada","year":"2023","unstructured":"Yamada, Y. et al. Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer. Sci. Transl. Med. 15, eadf6732 (2023).","journal-title":"Sci. Transl. Med."},{"key":"69308_CR37","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/nature07107","volume":"454","author":"A Meissner","year":"2008","unstructured":"Meissner, A. et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 454, 766\u2013770 (2008).","journal-title":"Nature"},{"key":"69308_CR38","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/nature04431","volume":"439","author":"E Vire","year":"2006","unstructured":"Vire, E. et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439, 871\u2013874 (2006).","journal-title":"Nature"},{"key":"69308_CR39","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1158\/0008-5472.CAN-05-2481","volume":"66","author":"KM McGarvey","year":"2006","unstructured":"McGarvey, K. M. et al. Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer Res 66, 3541\u20133549 (2006).","journal-title":"Cancer Res"},{"key":"69308_CR40","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/ng1950","volume":"39","author":"Y Schlesinger","year":"2007","unstructured":"Schlesinger, Y. et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat. Genet 39, 232\u2013236 (2007).","journal-title":"Nat. Genet"},{"key":"69308_CR41","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41588-021-01004-9","volume":"54","author":"K Adelman","year":"2022","unstructured":"Adelman, K. Nascent transcription as a predictor and driver of histone modifications. Nat. Genet 54, 223\u2013224 (2022).","journal-title":"Nat. Genet"},{"key":"69308_CR42","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41588-022-01026-x","volume":"54","author":"Z Wang","year":"2022","unstructured":"Wang, Z. et al. Prediction of histone post-translational modification patterns based on nascent transcription data. Nat. Genet 54, 295\u2013305 (2022).","journal-title":"Nat. Genet"},{"key":"69308_CR43","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41586-023-05780-8","volume":"615","author":"H Wang","year":"2023","unstructured":"Wang, H. et al. H3K4me3 regulates RNA polymerase II promoter-proximal pause-release. Nature 615, 339\u2013348 (2023).","journal-title":"Nature"},{"key":"69308_CR44","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/nature23881","volume":"549","author":"H Li","year":"2017","unstructured":"Li, H. et al. Polycomb-like proteins link the PRC2 complex to CpG islands. Nature 549, 287\u2013291 (2017).","journal-title":"Nature"},{"key":"69308_CR45","doi-asserted-by":"publisher","first-page":"E3415","DOI":"10.1073\/pnas.1400672111","volume":"111","author":"P Jermann","year":"2014","unstructured":"Jermann, P., Hoerner, L., Burger, L. & Schubeler, D. Short sequences can efficiently recruit histone H3 lysine 27 trimethylation in the absence of enhancer activity and DNA methylation. Proc. Natl. Acad. Sci. USA 111, E3415\u2013E3421 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"69308_CR46","doi-asserted-by":"publisher","first-page":"7983","DOI":"10.1074\/jbc.M110.194027","volume":"286","author":"W Yuan","year":"2011","unstructured":"Yuan, W. et al. H3K36 methylation antagonizes PRC2-mediated H3K27 methylation. J. Biol. Chem. 286, 7983\u20137989 (2011).","journal-title":"J. Biol. Chem."},{"key":"69308_CR47","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.molcel.2019.03.011","volume":"74","author":"A Laugesen","year":"2019","unstructured":"Laugesen, A., Hojfeldt, J. W. & Helin, K. Molecular mechanisms directing PRC2 recruitment and H3K27 methylation. Mol. Cell 74, 8\u201318 (2019).","journal-title":"Mol. Cell"},{"key":"69308_CR48","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.molcel.2011.03.025","volume":"42","author":"FW Schmitges","year":"2011","unstructured":"Schmitges, F. W. et al. Histone methylation by PRC2 is inhibited by active chromatin marks. Mol. Cell 42, 330\u2013341 (2011).","journal-title":"Mol. Cell"},{"key":"69308_CR49","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.molcel.2012.10.008","volume":"49","author":"IA Asangani","year":"2013","unstructured":"Asangani, I. A. et al. Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer. Mol. Cell 49, 80\u201393 (2013).","journal-title":"Mol. Cell"},{"key":"69308_CR50","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1038\/s41588-024-01893-6","volume":"56","author":"A Parolia","year":"2024","unstructured":"Parolia, A. et al. NSD2 is a requisite subunit of the AR\/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis. Nat. Genet 56, 2132\u20132143 (2024).","journal-title":"Nat. Genet"},{"key":"69308_CR51","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/nrg.2017.57","volume":"18","author":"Y Atlasi","year":"2017","unstructured":"Atlasi, Y. & Stunnenberg, H. G. The interplay of epigenetic marks during stem cell differentiation and development. Nat. Rev. Genet 18, 643\u2013658 (2017).","journal-title":"Nat. Rev. Genet"},{"key":"69308_CR52","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/ng.268","volume":"41","author":"J Wang","year":"2009","unstructured":"Wang, J. et al. The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation. Nat. Genet 41, 125\u2013129 (2009).","journal-title":"Nat. Genet"},{"key":"69308_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51966-7","volume":"15","author":"S Malla","year":"2024","unstructured":"Malla, S. et al. The scaffolding function of LSD1 controls DNA methylation in mouse ESCs. Nat. Commun. 15, 7758 (2024).","journal-title":"Nat. Commun."},{"key":"69308_CR54","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.celrep.2016.03.007","volume":"15","author":"T Zhang","year":"2016","unstructured":"Zhang, T. et al. G9a\/GLP complex maintains imprinted DNA methylation in embryonic stem cells. Cell Rep. 15, 77\u201385 (2016).","journal-title":"Cell Rep."},{"key":"69308_CR55","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41586-024-07103-x","volume":"627","author":"M Yamagishi","year":"2024","unstructured":"Yamagishi, M. et al. Mechanisms of action and resistance in histone methylation-targeted therapy. Nature 627, 221\u2013228 (2024).","journal-title":"Nature"},{"key":"69308_CR56","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.cell.2014.08.016","volume":"159","author":"D Gao","year":"2014","unstructured":"Gao, D. et al. Organoid cultures derived from patients with advanced prostate cancer. Cell 159, 176\u2013187 (2014).","journal-title":"Cell"},{"key":"69308_CR57","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1172\/JCI127961","volume":"129","author":"A Berger","year":"2019","unstructured":"Berger, A. et al. N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer. J. Clin. Invest 129, 3924\u20133940 (2019).","journal-title":"J. Clin. Invest"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69308-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69308-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69308-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T14:03:16Z","timestamp":1774879396000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69308-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,21]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["69308"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-69308-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,21]]},"assertion":[{"value":"22 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.S.R. has received research funding (to institution) from Janssen, Eli Lilly and Chimerix. M.C.H. served as a paid consultant\/received honoraria from Pfizer and Astra Zeneca and has received research funding from Merck, Novartis, Genentech, Promicell and Bristol Myers Squibb. H.B. has served as consultant\/advisory board member for Janssen, Astra Zeneca, Merck, Pfizer, Amgen, Bayer, Novartis, Daiichi Sankyo, Abbvie,\u00a0and has received research funding (to institution) from Janssen, Bristol Myers Squibb, Circle Pharma, Daiichi Sankyo, Novartis, Abbvie. All other authors declare no potential conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2992"}}